Researchers led by Dr. Debra Auguste, associate professor, biomedical engineering, in the Grove School of Engineering at The City College of New York, have identified a molecule that could lead to developing treatment for one of the most aggressive forms of breast cancer.
“No therapies are available to treat triple negative breast cancer cells and because of that patients have a poor prognosis,” said Professor Auguste, the recipient of a 2014 Presidential Early Career Award for Scientists and Engineers.
The Identification of ICAM-1 as a TNBC target and biomarker may lead to the development of a new strategy and platform for addressing a critical gap in TNBC patient care, she added.
The research is funded by a $2.5 million National Institutes of Health grant of which Professor Auguste is principal investigator. It includes researchers from Harvard Medical School, Emory University School of Medicine, Brigham and Women’s Hospital and Boston Children’s Hospital.
About The City College of New York
Since 1847, The City College of New York has provided low-cost, high-quality education for New Yorkers in a wide variety of disciplines. More than 16,000 students pursue undergraduate and graduate degrees in: the College of Liberal Arts and Sciences; the Bernard and Anne Spitzer School of Architecture; the School of Education; the Grove School of Engineering; the Sophie Davis School of Biomedical Education, and the Colin Powell School for Civic and Global Leadership. U.S. News, Princeton Review and Forbes all rank City College among the best colleges and universities in the United States.